Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:13 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524606 | NSE: BERLDRG

Beryl Drugs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹920.81Undervalued by 4,746.37%vs CMP ₹19.00

P/E (963.0) × ROE (6.3%) × BV (₹18.60) × DY (2.00%)

₹323.49Undervalued by 1,602.58%vs CMP ₹19.00
MoS: +94.1% (Strong)Confidence: 37/100 (Low)Models: 3 Under, 1 Fair, 3 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,089.6029%Under (+5634.7%)
Graham NumberEarnings₹2.8921%Over (-84.8%)
Earnings PowerEarnings₹3.6614%Over (-80.7%)
Net Asset ValueAssets₹18.669%Fair (-1.8%)
EV/EBITDAEnterprise₹40.6411%Under (+113.9%)
Earnings YieldEarnings₹0.209%Over (-98.9%)
Revenue MultipleRevenue₹41.737%Under (+119.6%)
Consensus (7 models)₹323.49100%Undervalued
Key Drivers: P/E of 963 makes PE-ROE unreliable — asset/earnings models are better benchmarks. | Wide model spread (₹0–₹1,090) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 18.3%

*Investments are subject to market risks

Investment Snapshot

42
Beryl Drugs Ltd scores 42/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health55/100 · Moderate
ROCE 10.2% AverageROE 6.3% AverageD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 26.4% Stable
Earnings Quality50/100 · Moderate
OPM stable around 7% Steady
Quarterly Momentum15/100 · Weak
Revenue (4Q): -7% YoY DecliningProfit (4Q): -88% YoY DecliningOPM: -5.2% (down 16.1% YoY) Margin pressure
Industry Rank30/100 · Weak
P/E 963.0 vs industry 53.8 Premium to peersROCE 10.2% vs industry 16.4% AverageROE 6.3% vs industry 15.2% Below peers3Y sales CAGR: 13% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:13 am

Market Cap 9.63 Cr.
Current Price 19.0
Intrinsic Value₹323.49
High / Low 30.0/15.9
Stock P/E963
Book Value 18.6
Dividend Yield0.00 %
ROCE10.2 %
ROE6.30 %
Face Value 10.0
PEG Ratio52.53

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Beryl Drugs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Beryl Drugs Ltd 9.63 Cr. 19.0 30.0/15.9963 18.60.00 %10.2 %6.30 % 10.0
Gujarat Inject (Kerala) Ltd 120 Cr. 82.1 82.1/17.0481 6.930.00 %13.5 %11.0 % 10.0
Achyut Healthcare Ltd 132 Cr. 5.62 6.80/3.00308 1.340.00 %2.26 %1.77 % 1.00
Adline Chem Lab Ltd 7.31 Cr. 12.5 19.1/7.60244 2.750.00 %%% 10.0
Sequent Scientific Ltd 8,768 Cr. 201 260/111203 32.20.00 %8.47 %3.21 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Beryl Drugs Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 8.196.098.188.097.663.216.295.645.405.224.835.163.85
Expenses 7.475.827.057.376.873.195.305.084.814.724.284.434.05
Operating Profit 0.720.271.130.720.790.020.990.560.590.500.550.73-0.20
OPM % 8.79%4.43%13.81%8.90%10.31%0.62%15.74%9.93%10.93%9.58%11.39%14.15%-5.19%
Other Income 0.000.000.000.000.000.000.000.000.000.000.000.000.00
Interest 0.120.060.120.100.110.130.210.120.120.080.100.080.09
Depreciation 0.220.150.280.290.310.320.280.330.310.320.380.390.32
Profit before tax 0.380.060.730.330.37-0.430.500.110.160.100.070.26-0.61
Tax % 60.53%-16.67%27.40%18.18%16.22%-16.28%26.00%90.91%62.50%-50.00%71.43%96.15%-72.13%
Net Profit 0.140.060.530.270.31-0.350.370.010.050.150.020.01-0.17
EPS in Rs 0.280.121.050.530.61-0.690.730.020.100.300.040.02-0.34

Last Updated: March 3, 2026, 11:50 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 1:15 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 14.5413.2312.9910.9015.0812.8112.7814.0314.4826.8426.7321.1519.06
Expenses 13.7712.5012.4910.9614.0411.7811.8712.5814.0424.8424.4519.9117.48
Operating Profit 0.770.730.50-0.061.041.030.911.450.442.002.281.241.58
OPM % 5.30%5.52%3.85%-0.55%6.90%8.04%7.12%10.33%3.04%7.45%8.53%5.86%8.29%
Other Income 0.180.180.370.270.690.240.230.640.160.270.401.410.00
Interest 0.200.260.210.200.130.150.320.470.460.470.470.540.35
Depreciation 0.320.520.410.380.330.320.661.271.090.811.201.251.41
Profit before tax 0.430.130.25-0.371.270.800.160.35-0.950.991.010.86-0.18
Tax % 37.21%38.46%32.00%18.92%22.05%26.25%68.75%31.43%-30.53%22.22%23.76%33.72%
Net Profit 0.270.080.17-0.450.990.590.050.24-0.660.770.770.580.01
EPS in Rs 0.530.160.34-0.891.951.160.100.47-1.301.521.521.140.02
Dividend Payout % -0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-70.37%112.50%-364.71%320.00%-40.40%-91.53%380.00%-375.00%216.67%0.00%-24.68%
Change in YoY Net Profit Growth (%)0.00%182.87%-477.21%684.71%-360.40%-51.12%471.53%-755.00%591.67%-216.67%-24.68%

Beryl Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:5%
5 Years:12%
3 Years:16%
TTM:-16%
Compounded Profit Growth
10 Years:22%
5 Years:63%
3 Years:42%
TTM:-62%
Stock Price CAGR
10 Years:-3%
5 Years:29%
3 Years:35%
1 Year:-24%
Return on Equity
10 Years:3%
5 Years:3%
3 Years:8%
Last Year:6%

Last Updated: September 5, 2025, 2:41 pm

Balance Sheet

Last Updated: December 10, 2025, 3:56 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 5.095.095.095.095.095.095.095.095.095.095.095.095.09
Reserves 1.331.401.570.791.572.432.532.842.202.973.834.414.37
Borrowings 1.531.721.691.721.483.255.235.125.294.545.094.074.30
Other Liabilities 1.792.711.802.852.693.804.075.605.254.923.482.393.65
Total Liabilities 9.7410.9210.1510.4510.8314.5716.9218.6517.8317.5217.4915.9617.41
Fixed Assets 2.792.432.442.252.221.968.607.526.046.036.176.207.62
CWIP 0.130.240.000.000.086.240.000.000.000.000.000.000.83
Investments 0.730.680.680.490.220.480.560.120.160.150.000.000.00
Other Assets 6.097.577.037.718.315.897.7611.0111.6311.3411.329.768.96
Total Assets 9.7410.9210.1510.4510.8314.5716.9218.6517.8317.5217.4915.9617.41

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.000.70-0.130.37-0.103.350.180.34-0.292.480.822.64
Cash from Investing Activity + 0.000.020.170.32-0.03-5.01-1.550.260.54-1.30-1.08-0.40
Cash from Financing Activity + 0.00-0.09-0.23-0.19-0.361.621.67-0.54-0.43-1.170.10-1.55
Net Cash Flow 0.000.63-0.190.50-0.49-0.040.300.06-0.180.01-0.160.69
Free Cash Flow 0.000.47-0.330.19-0.01-2.87-1.700.100.101.73-0.511.35
CFO/OP 0%125%6%-833%1%350%36%25%-43%127%45%227%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-0.76-0.99-1.19-1.78-0.44-2.22-4.32-3.67-4.85-2.54-2.81-2.83

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 64.26102.08100.59102.47116.9198.0298.53118.11112.1793.83103.5194.23
Inventory Days 52.8464.3465.28151.2953.1039.74486.671,135.00245.67
Days Payable 50.5969.9134.3465.2457.0393.60755.171,110.00758.08
Cash Conversion Cycle 66.5196.50131.54188.52112.9744.16-169.97143.11112.17-418.57103.5194.23
Working Capital Days 36.9038.3558.4467.3171.89-6.5513.9938.7663.5246.5157.9068.00
ROCE %8.42%5.20%5.56%-2.26%11.94%9.94%4.06%2.86%-3.82%11.60%11.05%10.15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 26.38%26.38%26.38%26.38%26.38%26.38%26.38%26.38%26.38%26.38%26.38%26.38%
Public 73.61%73.61%73.62%73.62%73.61%73.61%73.62%73.62%73.61%73.61%73.62%73.62%
No. of Shareholders 6,8946,8006,8056,8527,2577,3257,3647,4297,4317,4157,4467,409

Shareholding Pattern Chart

No. of Shareholders

Beryl Drugs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 18Mar 17
FaceValue 10.0010.00
Basic EPS (Rs.) 1.960.00
Diluted EPS (Rs.) 1.960.00
PBDIT Margin (%) 10.561.89
PBIT Margin (%) 8.50-1.38
PBT Margin (%) 7.67-3.12
Net Profit Margin (%) 6.21-3.59
NP After MI And SOA Margin (%) 6.21-3.59
Interest Coverage Ratio (X) 10.28-0.79
Interest Coverage Ratio (Post Tax) (X) 8.50-1.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Beryl Drugs Ltd. is a Public Limited Listed company incorporated on 24/08/1993 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN) is L02423MP1993PLC007840 and registration number is 007840. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 21.15 Cr. and Equity Capital is Rs. 5.09 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals133, Kanchan Bagh, Indore Madhya Pradesh 452001Contact not found
Management
NamePosition Held
Mr. Sudhir SethiChairman & Director
Mr. Sanjay SethiManaging Director
Mr. Abhinav NaikIndependent Director
Mrs. Shreya SarafIndependent Woman Director

FAQ

What is the intrinsic value of Beryl Drugs Ltd and is it undervalued?

As of 10 April 2026, Beryl Drugs Ltd's intrinsic value is ₹323.49, which is 1602.58% higher than the current market price of ₹19.00, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (6.30 %), book value (₹18.6), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Beryl Drugs Ltd?

Beryl Drugs Ltd is trading at ₹19.00 as of 10 April 2026, with a FY2026-2027 high of ₹30.0 and low of ₹15.9. The stock is currently near its 52-week low. Market cap stands at ₹9.63 Cr..

How does Beryl Drugs Ltd's P/E ratio compare to its industry?

Beryl Drugs Ltd has a P/E ratio of 963, which is above the industry average of 53.84. This significantly elevated P/E suggests the market expects strong future growth, or the stock may be overpriced relative to current earnings.

Is Beryl Drugs Ltd financially healthy?

Key indicators for Beryl Drugs Ltd: ROCE of 10.2 % is moderate; ROE of 6.30 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Beryl Drugs Ltd profitable and how is the profit trend?

Beryl Drugs Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹21 Cr. Compared to ₹-1 Cr in Mar 2022, the net profit shows an improving trend.

Does Beryl Drugs Ltd pay dividends?

Beryl Drugs Ltd has a dividend yield of 0.00 % at the current price of ₹19.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Beryl Drugs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports